• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Study maps 8 long-COVID symptom patterns in adults

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/covid-19/study-maps-8-long-covid-symptom-patterns-adults

Study maps 8 long-COVID symptom patterns in adults



Laine Bergeson


Today at 3:48 p.m.

COVID-19

Public Health

A large, prospective US
study has identified eight distinct long-COVID trajectories, highlighting the diverse manifestations of the condition and laying the groundwork for future studies to evaluate risk factors and biomarkers that could explain variations in symptoms and identify therapeutic targets.

The study, led by a team at Massachusetts General Hospital, followed 3,659 participants (69% female) from the National Institutes of Health Researching COVID to Enhance Recovery (RECOVER) Adult Cohort. The National Institutes of Health established RECOVER to address COVID as a global health priority.

Researchers tracked participants from 3 to 15 months after their first COVID infection. Almost all participants (99.6%) were infected with the Omicron variant. The enrollment period spanned October 29, 2021, to June 27, 2023.

Overall, 10.3% of participants met the criteria for long COVID at three months, and 81% of them continued to report persistent or fluctuating symptoms more than a year later.

The findings were published last week in Nature Communications.

14% of participants experienced worsening symptoms over time


Eight symptom trajectories emerged. About 5% of the infected cohort had “persistent, high” symptom burden across the entire 15-month period, while 12% experienced “intermittently high” symptoms. Another 10% showed moderate symptoms that gradually improved, and 9% experienced low-level symptoms that largely resolved by month six.

Notably, 14% followed worsening or delayed-worsening trajectories, including a group whose symptoms remained minimal until spiking at month 15.

The study compared infected participants with an uninfected cohort over the same period. While persistent and improving symptoms were less common among uninfected adults, some worsening patterns appeared in both groups, raising the possibility that not all symptom increases reflect long COVID.

The authors note several study limitations, including reliance on symptom surveys collected every three months (which may not have captured more granular, day-to-day changes), and the inability to capture trajectories beyond 15 months. Still, the large sample size, representative population, detailed symptom questionnaire, standardized long-COVID index, and minimal loss to follow up provide a clearer picture of long COVID’s different trajectories.

In a Mass General Brigham (MGB) press release, corresponding author Bruce Levy, MD, of the MGB Department of Medicine, said, “Our findings will help determine what resources are needed for clinical and public health support of individuals with long COVID and will also inform efforts to understand long COVID’s biological basis.”
 
Back
Top Bottom